News

Clarametyx Biosciences Announces $33 Million Series A Financing to Advance Anti-Biofilm Biologics for Serious Bacterial Infections

Newly established relationship with Cystic Fibrosis Foundation enables…

Clarametyx Announces Positive Early Phase 1 Safety Findings on CMTX-101, Immune-Enabling Antibody Therapy

COLUMBUS, Ohio – June 1, 2023 – Clarametyx Biosciences, Inc. (“Clarametyx”), a…

Clarametyx Biosciences Announces Changes to Its Scientific Advisory Board

Renowned vaccine R&D expert Dr. Jeffrey Almond joins to advise on…

Clarametyx Initiates Phase 1 Study of Immune-Enabling Antibody Therapy CMTX-101 Against Community-Acquired Bacterial Pneumonia

COLUMBUS, Ohio – November 30, 2022 – Clarametyx Biosciences Inc.…

Clarametyx Announces FDA Acceptance of Investigational New Drug (IND) Application for Phase 1 Study of Immune-Enabling Antibody Therapy CMTX-101

COLUMBUS, Ohio – October 5, 2022 – Clarametyx Biosciences Inc. (“Clarametyx”),…

Clarametyx Biosciences Expands Board of Directors with Appointment of Financial Executive Michael Layman

Mr. Layman joins as an independent director as the company continues to…